In Battle For Diabetes Drug Market, Domestic Companies Lack Resources
This article was originally published in PharmAsia News
Executive SummaryAs China's growing diabetes population attracts multinational drug giants, domestic companies' lack of human resources, scale and capital continues to hamper competitiveness
You may also be interested in...
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker.
US FDA’s latest effort to provide guidance for consumers on pharmacogenomics tests underscores the challenges the agency faces in the absence of a clear regulatory framework for lab-developed tests – and with no easy mechanism to update labels for off-patent drugs.